Trial document



drksid header

  DRKS00000287

Trial Description

start of 1:1-Block title

Title

Preparation of Neuroplant® 300mg N in film-coated tablets (St. John´s wort, SJW) in the treatment of mild to moderate Major Depressive Disorder (MDD) in adolescents from 12 to 17 years (inclusive): a parallel group, randomized, double-blind, placebo (PBO)-controlled, multicentre clinical trial to evaluate the efficacy, safety, somatic and behavioral Adverse Events (AEs) and pharmacokinetics of SJW in mild to moderate MDD in adolescents.

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

DEMIJO

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Labelled as a phytopharmacon in Germany, SJW has not been put through controlled clinical trials to demonstrate its efficacy, safety and recommended dose in minors in order to obtain its license according to German regulatory procedures. Therefore SJW is labelled for the use in children and adolescents, it is the most frequent prescribed antidepressant in children and adolescents, but efficacy and safety has not been proven as it would be required in case of a synthetic antidepressant. Therefore a sound RCT on SJW in adolescents is a public health imperative in Germany.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

This is a Phase 4, multicenter, randomized, double-blind, PBO-controlled, study in adolescents aged 12 to 17 years meeting DSM-IV-TR defined criteria for mild to moderate major depressive disorder (MDD). Safety and efficacy of orally delivered SJW (Neuroplant® 300mg N) will be assessed. The study consists of 2 periods: Period I is a screening period; Period II is a 12-week double-blind acute therapy period. The total duration of the study is approximately 38 weeks. The total number of randomly assigned patients in this study is anticipated to be approximately 216, with approximately 108 assigned to each of 2 arms: SJW (Neuroplant® 300mg N) and PBO.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00000287
  •   2009/12/09
  •   2009/07/09
  •   yes
  •   Approved
  •   301/09, Ethik-Kommission der Universität Ulm
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   U1111-1112-8086 
  •   2009-013956-62 
  •   99665363  (ISRCTN)
  •   DEMIJO  (Universitätsklinikum Ulm)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   F32.0 -  Mild depressive episode
  •   F32.1 -  Moderate depressive episode
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   SJW (600mg/d up to 900mg/d) orally; duration of intervention per patient: 12 weeks
  •   placebo orally; duration of intervention: 12 weeks
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, investigator/therapist, assessor
  •   Placebo
  •   Other
  •   Parallel
  •   IV
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Assessment of efficacy of SJW (Neuroplant® 300mg N) compared with PBO in the acute treatment of adolescents who meet criteria for mild to moderate MDD.
Primary efficacy endpoint: CGI-I dichotomized 1-2 vs. >= 3 at week 12

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Further measures of efficacy, safety and pharmacokinetics of SJW. Additionally quality of life and social functioning after treatment with SJW.
Key secondary endpoint(s): Improvement in CDRS-R total score and other psychometric scales indicating improvement of symptoms of depression and social functioning at week 6 and 12, hyperforin kinetics at week 6, metabolizer pheno-type
Assessment of safety: Adverse Events (AEs) by monitoring and usual documentation acc. GCP, Adverse Event questionnaires (PAERS, C-SSRS), SHBQ for self-harming/suicidal ideations or attempts

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2010/11/03
  •   238
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   12   Years
  •   17   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Participant is able to understand the study and its procedures according to his or her age. Caregivers have to be able to understand the study, the study procedures, individual consequences for their child.
Written consent and assent of the caregivers and participants which is dated by the caregivers/participants before any study exam or procedure is conducted.
Adolescents with mild to moderate MDD
Symptoms of depression stable for about 6 weeks before entering the trial.
Female patients must test negative for pregnancy during screening at baseline-visit. Furthermore, female patients must agree to abstain from sexual activity or to use a reliable method of birth control as determined by the investigator during the study.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Other psychiatric disorders
Acute risk of suicide in the opinion of the investigator at Visit 1
Other non-psychiatric disorders as specified as follows:
diagnosis of epilepsy, any intracranial disease
Q above 80
Start of psychotherapy
Treatment with other AD or psychopharmacologically active substances
Contraindications or hypersensitivity to SJW
Treatment with drugs that interact with SJW or CYP3A4

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Ulm Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie
    • Steinhövelstr. 5
    • 89075  Ulm
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Vivantes Klinikum im FriedrichshainKlinik für Kinder- u. Jugendpsychiatrie, Psychotherapie und Psychosomatik
    • Mr.  Professor Dr. med.  Michael  Kölch 
    • Landsberger Allee 49, Haus 8
    • 10249  Berlin
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Universitätsklinikum Ulm Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie
    • Mr.  Professor Dr. med.  Michael  Kölch 
    • Steinhövelstr. 5
    • 89075  Ulm
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Projektträger im DLR Gesundheitsforschung
    • Heinrich-Konen-Str. 1
    • 53227  Bonn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting stopped after recruiting started
  •   2012/08/29
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.